The efficacy and tolerability of glecaprevir/pibrentasvir treatment in a real-world chronic hepatitis C patients cohort

Serkan Yaras; Mehmet Demir; Sezgin Barutcu; Abdullah Emre Yildirim; Selim Gurel; Enver Ucbilek; Ilkce Akgun Kurtulmus; Meral Akdogan Kayhan; Sezgin Vatansever; Haydar Adanir; Nilay Danis; Serkan Duman; Ilker Turan; Derya Ari; Sukran Kose; Huseyin Alkim; Muhsin Murat Harputluoglu; Feyza Dilber; Murat Akyildiz; Arif Mansur Cosar; Serdar Durak; Goktug Sirin; Ayse Kefeli; Hale Gokcan; Ufuk Avcioglu; Talat Ayyildiz; Orhan Sezgin; Mesut Akarsu; Dinc Dincer; Fatih Guzelbulut; Fulya Gunsar; Ulus Salih Akarca; Ramazan Idilman

doi:10.14744/hf.2023.2023.0001

The efficacy and tolerability of glecaprevir/pibrentasvir treatment in a real-world chronic hepatitis C patients cohort

Hepatol Forum. 2023 Sep 20;4(3):92-96. doi: 10.14744/hf.2023.2023.0001. eCollection 2023.

Authors

Serkan Yaras¹, Mehmet Demir², Sezgin Barutcu³, Abdullah Emre Yildirim⁴, Selim Gurel⁵, Enver Ucbilek¹, Ilkce Akgun Kurtulmus⁶, Meral Akdogan Kayhan⁷, Sezgin Vatansever⁸, Haydar Adanir⁹, Nilay Danis¹⁰, Serkan Duman¹¹, Ilker Turan¹², Derya Ari⁷, Sukran Kose¹³, Huseyin Alkim¹⁴, Muhsin Murat Harputluoglu¹⁵, Feyza Dilber¹⁶, Murat Akyildiz¹⁷, Arif Mansur Cosar¹⁸, Serdar Durak¹⁸, Goktug Sirin¹⁹, Ayse Kefeli²⁰, Hale Gokcan²¹, Ufuk Avcioglu²², Talat Ayyildiz²², Orhan Sezgin¹, Mesut Akarsu²³, Dinc Dincer²⁴, Fatih Guzelbulut²⁵, Fulya Gunsar¹², Ulus Salih Akarca¹², Ramazan Idilman²¹

Affiliations

¹ Department of Gastroenterology, Mersin University, School of Medicine, Mersin, Turkiye.
² Department of Gastroenterology, Mustafa Kemal University, School of Medicine, Hatay, Turkiye.
³ Department of Medical Sciences, Gaziantep University, School of Medicine, Gaziantep, Turkiye.
⁴ Department of Gastroenterology, Memorial Bahcelievler Hospital, Istanbul, Turkiye.
⁵ Department of Internal Medicine, Uludag University, School of Medicine, Bursa, Turkiye.
⁶ Department of Internal Medicine, Ege University, School of Medicine, Izmir, Turkiye.
⁷ Division of Gastroenterology, Department of Internal Medicine, Faculty of Health Sciences, Ankara City Hospital, Ankara, Turkiye.
⁸ Department of Gastroenterology, Katip Celebi University, Ataturk Training and Research Hospital, Izmir, Turkiye.
⁹ Department of Internal Medicine, Akdeniz University, School of Medicine, Antalya, Turkiye.
¹⁰ Division of Gastroenterology and Hepatology, Department of Medicine, Johns Hopkins University, Baltimore, USA.
¹¹ Department of Gastroenterology, Toros State Hospital, Mersin, Turkiye.
¹² Department of Gastroenterology, Ege University, School of Medicine, Izmir, Turkiye.
¹³ Department of Infectious Diseases and Clinical Microbiology, Dokuz Eylul University, School of Medicine, Izmir, Turkiye.
¹⁴ Department of Gastroenterology, Sisli Etfal Training and Research Hospital, Istanbul, Turkiye.
¹⁵ Department of Internal Medicine, Inonu University, School of Medicine, Malatya, Turkiye.
¹⁶ Department of Gastroenterology, Marmara University, School of Medicine, Istanbul, Turkiye.
¹⁷ Department of Gastroenterology, Koc University, School of Medicine, Istanbul, Turkiye.
¹⁸ Department of Gastroenterology, Karadeniz Technical University, School of Medicine, Trabzon, Turkiye.
¹⁹ Department of Gastroenterology, Kocaeli University, School of Medicine, Kocaeli, Turkiye.
²⁰ Department of Gastroenterology, Tokat Gaziosmanpasa University, School of Medicine, Tokat, Turkiye.
²¹ Department of Gastroenterology, Ankara University, School of Medicine, Ankara, Turkiye.
²² Department of Gastroenterology, Ondokuz Mayis University, School of Medicine, Samsun, Turkiye.
²³ Department of Gastroenterology, Dokuz Eylul, School of Medicine, Izmir, Turkiye.
²⁴ Department of Gastroenterology, Akdeniz University, School of Medicine, Antalya, Turkiye.
²⁵ Departments of Gastroenterology and Pathology, Haydarpasa Numune Training and Research Hospital, Istanbul, Turkiye.

Abstract

Background and aim: The aims of the present study were to evaluate the real-life efficacy and tolerability of glecaprevir (GLE)/pibrentasvir (PIB) in the treatment of patients with chronic hepatitis C (CHC).

Materials and methods: Between May 2019 and May 2022, 686 patients with CHC, treated with GLE/PIB combination from 21 participating centers in Turkiye, were enrolled in the study.

Results: All patients were Caucasian, and their median age was 56 years. At the start of GLE/PIB treatment, the median serum Hepatitis C virus RNA and serum alanine amino transaminase (ALT) levels were 6.74 log10 IU/mL and 47 U/L, respectively. Fifty-three percent of the patients were infected with genotype 1b, followed by genotype 3 (17%). Diabetes was the more common concomitant disease. The sustained virological response (SVR12) was 91.4% with intent-to-treat analysis and 98.5% with per protocol analysis. The SVR12 rates were statistically significant differences between the patients who were i.v. drug users and non-user (88.0% vs. 98.8%, p=0.025). From the baseline to SVR12, the serum ALT levels and Model for End-Stage Liver Disease score were significantly improved (p<0.001 and p=0.014, respectively). No severe adverse effect was observed.

Conclusion: GLE/PIB is an effective and tolerable treatment in patients with CHC.

Keywords: Chronic hepatitis C; glecaprevir-pibrentasvir; real-life experience.